Abstract
Gene therapy is a rapidly developing field in which recombinant nucleic acid sequences are introduced to individuals to regulate, repair, replace, add or delete a genetic sequence. Recombinant adeno-associated viral (AAV) vectors, especially AAV2, are frequently used in gene therapy. Knowledge on the biodistribution and potential shedding of AAV2 is crucial to evaluate the risks of infection with the viral vector for the patient and the environment. Literature was analysed for biodistribution and shedding data for AAV2. Preclinical and clinical studies were included with a focus on the influence of the administration route on spreading. Based on biodistribution and shedding data, a qualitative model for the biodistribution and shedding of AAV2 related to the administration route is presented. It is concluded that biodistribution and shedding of AAV2 depend on the route of administration. Some routes lead to local biodistribution and thus to no shedding or shedding via one route only. Other routes lead to systemic biodistribution and to shedding via several excretion routes. The qualitative model presented can help to determine the possible biodistribution in the body and the risk of shedding via the different excretion routes. In addition, it can help to predict the different shedding routes after a certain administration route of AAV2 and thus in deciding which studies are warranted or which safety precautions are needed after administration to patients.
Keywords: Viral vectors, adeno-associated virus, excretion, distribution, gene therapy, qualitative model
Current Gene Therapy
Title: Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Volume: 10 Issue: 2
Author(s): Esther F.A. Brandon, Harm P.H. Hermsen, Jan C.H. van Eijkeren and Birgitte Tiesjema
Affiliation:
Keywords: Viral vectors, adeno-associated virus, excretion, distribution, gene therapy, qualitative model
Abstract: Gene therapy is a rapidly developing field in which recombinant nucleic acid sequences are introduced to individuals to regulate, repair, replace, add or delete a genetic sequence. Recombinant adeno-associated viral (AAV) vectors, especially AAV2, are frequently used in gene therapy. Knowledge on the biodistribution and potential shedding of AAV2 is crucial to evaluate the risks of infection with the viral vector for the patient and the environment. Literature was analysed for biodistribution and shedding data for AAV2. Preclinical and clinical studies were included with a focus on the influence of the administration route on spreading. Based on biodistribution and shedding data, a qualitative model for the biodistribution and shedding of AAV2 related to the administration route is presented. It is concluded that biodistribution and shedding of AAV2 depend on the route of administration. Some routes lead to local biodistribution and thus to no shedding or shedding via one route only. Other routes lead to systemic biodistribution and to shedding via several excretion routes. The qualitative model presented can help to determine the possible biodistribution in the body and the risk of shedding via the different excretion routes. In addition, it can help to predict the different shedding routes after a certain administration route of AAV2 and thus in deciding which studies are warranted or which safety precautions are needed after administration to patients.
Export Options
About this article
Cite this article as:
F.A. Brandon Esther, P.H. Hermsen Harm, C.H. van Eijkeren Jan and Tiesjema Birgitte, Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach, Current Gene Therapy 2010; 10 (2) . https://dx.doi.org/10.2174/156652310791111047
DOI https://dx.doi.org/10.2174/156652310791111047 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Protein & Peptide Letters Targeting Translation for Treatment of Cancer - A Novel Role for IRES?
Current Cancer Drug Targets Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery 4,7-Dihydroindole: A Synthon for the Preparations of 2-Substituted Indoles
Current Organic Synthesis Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Use of Metallomics in Environmental Pollution Assessment Using Mice Mus musculus/Mus spretus as Bioindicators
Current Analytical Chemistry Agaricus blazei Water Extracts as Alternative Medicines
Current Pharmaceutical Analysis Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals In vivo 19F MR Studies of Fluorine Labeled Photosensitizers in a Murine Tumor Model
Current Drug Discovery Technologies Impact of DMPEI on Biofilm Adhesion on Latex Urinary Catheter
Recent Patents on Biotechnology Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Cross Bridging Proteins in Nature and their Utilization in Bio- and Nanotechnology
Current Protein & Peptide Science The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Air Pollution and Lung Cancer
Current Respiratory Medicine Reviews Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry